New aspects of molecular imaging in prostate cancer

Considering the wide diffusion of PCa in the Europe and the United States, the presence of these new diagnostic techniques able to detect the disease with high sensitivity and specificity might have a clinical impact on the management of patients. PET/CT imaging with new radiopharmaceuticals can implement the patient management identifying lesion(s) not detectable with conventional imaging procedures. In this review article will be discussed the most promising new PET radiopharmaceuticals (68 Ga-PSMA-11, 18 F-FACBC, 68 Ga-RM2) available at the moment, focusing the attention on their accuracy and their impact on treatment strategy.